TOKYO, LONDON and BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around...
PRINCETON, N.J. and TOKYO, April 2, 2024 /PRNewswire/ -- Kyowa Kirin Co., Ltd. (TSE: 4151) a Japan-based global specialty pharmaceutical company (J-GSP) creating innovative medical solutions utilizing the latest biotechnology, today announced that pre-clinical data of tivozanib (KHK-4951), an investigational product, assessing the ocular pharmacokinetics of a novel tivozanib eye drop for neovascular age-related macular degeneration (nAMD), will be presented at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting to be held in Seattle, Washington from May 5-9, 2024.
The US Food and Drug Administration (FDA) is proposing the creation of two lists of drugs or drug categories that are difficult to compound under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act (FD&C Act), as well as criteria for inclusion on the lists.
North Carolina has proved an attractive destination for biopharma companies large and small in recent years, ginning up investments and site commitments from the likes of Eli Lilly, Fujifilm Diosynth, Thermo Fisher, Amgen and other drugmakers.
PRINCETON, N.J. and TOKYO, Feb. 14, 2024 /PRNewswire/ -- Kyowa Kirin Co., Ltd. (TSE: 4151) today announced that disease education and data from the Phase 2b study of rocatinlimab (AMG451/KHK4083), an investigational product being studied in patients with moderate-to-severe atopic dermatitis, will be presented at the upcoming American Academy of Dermatology (AAD) 2024 Annual Meeting in San Diego from March 8-12, 2024.
TOKYO, Feb. 6, 2024 /PRNewswire/ -- Kyowa Kirin Co., Ltd. (TSE: 4151) today announced the enrollment of the first patient in a Phase 2 clinical trial, multi-center, randomized, double-masked, parallel group study of tivozanib eye drops (KHK4951). This study investigates the efficacy and safety of KHK4951 in patients with diabetic macular edema (DME). Tivozanib, the active ingredient of KHK4951 is a small-molecule vascular endothelial growth factor receptor (VEGFR)-1, -2, and -3 tyrosine kinase inhibitor (TKI) discovered and developed by Kyowa Kirin. KHK4951 is a novel nano-crystalized tivozanib eye drops designed to deliver it efficiently to the posterior ocular tissues and is being developed as a potential treatment option for neovascular (wet) age-related macular degeneration (nAMD) and DME. An oral formulation of tivozanib is currently marketed as FOTIVDA? in the U.S. by AVEO Oncology, an LG Chem Company, and in Europe by EUSA Pharma (UK) Ltd. for another indication.
Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseases
Boehringer ends week with 3rd deal, this time with Kyowa Kirin
Hoc Analysis from MAVORIC Trial Sheds Light on Burden of T-Cell Lymphoma
Kyowa Kirin Responds to NICE’s Publication of Appraisal Document for CRYSVITA